Boston Scientific Corporation $BSX Shares Purchased by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. increased its Boston Scientific stake by 1,393.9% in the third quarter, purchasing 142,830 additional shares for a total position of 153,077 shares valued at $6.68 million. Institutional investors collectively own 89.07% of BSX.
• Boston Scientific insiders purchased 194,522 shares worth approximately $9.39 million in the latest quarter, including significant buys by CEO Michael F. Mahoney and Director David C. Habiger.
• The company exceeded quarterly earnings and revenue estimates, reporting $0.86 in EPS and $5.44 billion in revenue, while revenue grew 7.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.31, despite the stock opening at $41.55.

Congress Asset Management Co. boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 1,393.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,077 shares of the medical equipment provider's stock after purchasing an additional 142,830 shares during the period. Congress Asset Management Co.'s holdings in Boston Scientific were worth $6,682,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BSX. Central Pacific Bank Trust Division boosted its position in Boston Scientific by 1,031.2% during the third quarter. Central Pacific Bank Trust Division now owns 4,717 shares of the medical equipment provider's stock valued at $206,000 after purchasing an additional 4,300 shares during the last quarter. Neville Rodie & Shaw Inc. raised its stake in shares of Boston Scientific by 35.2% during the 3rd quarter. Neville Rodie & Shaw Inc. now owns 24,295 shares of the medical equipment provider's stock worth $1,060,000 after purchasing an additional 6,325 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Boston Scientific by 50.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 6,549 shares of the medical equipment provider's stock worth $286,000 after purchasing an additional 2,209 shares in the last quarter. QRG Capital Management Inc. grew its stake in shares of Boston Scientific by 129.4% in the second quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider's stock valued at $16,031,000 after buying an additional 211,855 shares in the last quarter. Finally, Andra AP fonden increased its holdings in Boston Scientific by 13.9% during the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider's stock worth $8,264,000 after buying an additional 23,694 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger bought 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock valued at $9,385,210 in the last quarter. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Down 1.5%

Boston Scientific stock opened at $41.55 on Thursday. The company's 50-day moving average price is $46.72 and its two-hundred day moving average price is $50.90. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market cap of $60.21 billion, a P/E ratio of 16.82, a P/E/G ratio of 1.01 and a beta of 0.58. Boston Scientific Corporation has a twelve month low of $41.50 and a twelve month high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the firm posted $0.75 EPS. The company's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts expect that Boston Scientific Corporation will post 3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent analyst reports. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Barclays initiated coverage on Boston Scientific in a report on Tuesday. They set an "equal weight" rating and a $48.00 price target for the company. Sanford C. Bernstein restated an "outperform" rating and issued a $54.00 price objective on shares of Boston Scientific in a research note on Saturday. Weiss Ratings reiterated a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Finally, Needham & Company LLC decreased their target price on Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Twenty-two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.31.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.